Nuclear NRF2 expression due to activation of NRF2-ARE signalling may promote tumor progression and drug resistance, and hence NRF2 inhibition could be a strategic path in cancer treatment[54,58,196]. The gene discussed is NFE2L2; the disease is neoplasm.